The present study was designed to evaluate the protective role of the antioxidants antox against Sorafenib-celllular toxicity in adult male albino rats. One hundred and twenty mature male albino rats divided into 4 equal groups were used in this study. The 1st group was kept as normal control group, the 2nd group was given anti-cancer drug sorafenib orally and daily for successive 2 weeks in adose of (10 mg/kg b.wt.), the 3rd group was administered the antioxidant drug antox orally and daily for 2 weeks in a dose of (10 mg/kg b.wt.), the 4th group was given the two drugs together in their recommended doses. Blood samples were collected from 5 rats of each group at 1st,3rd days and 1st, 2nd, 3rd and 4th weeks post end of treatment and were subjected to biochemical assays including: oxidative and antioxidative parameters (malondealdehyde (MDA), reduced glutathione (GSH) activity, (GPX) glutathione peroxidase, Catalase (CAT), souperoxide dismutase (SOD) and total antioxidants capacity and genotoxicity (Comet assay test. Treatment with sorafenib alone resulted in a significant increase in MDA, CAT, SOD and Gpx level and total antioxidants activity. The activity of reduced (GSH) is significantly decreased in sorafenib treated group compared to control group. Treatment for two weeks with antox after sorafenib elicited a significant decrease in MDA, GPX, SOD, CAT as well as a significant increase in serum GSH, total antioxidants activity and Comet assay revealed that sorafenib treated group showed a significant increase in comet %,tail length, DNA tail % and tail moment compared with control and other treated groups.